New immunotherapy platform for all solid tumors
Information
Teclison develops a new platform of immunotherapy that is suitable for all solid tumors. Using a new tumor necrosis-inducing agent, our cancer treatment can trigger over 100X expansion of anti-tumor T cells in patient's blood, which enhanced the efficacy of anti-PD-1 immunotherapy and salvaged patients who failed anti-PD-1 immunotherapy. Using Next Generation Sequencing to interrogate the expanded T cells, multiple unique T cell receptor sequences have been identified, which can be used to derive the cognate immunogenic tumor neoantigens with 3D-protein modeling and AI-based tools. The newly discovered tumor neoantigens could serve as targets to develop a variety of new cancer therapeutics for cancer. The whole platform aims to spare cancer patients from chemotherapy-related toxicities, to bring a better life and a longer survival.
This is an ATTEND IN PERSON session, taking place at Future X Stage. If you have any questions about the session, please send an email to Customer Success Team.
